MaxCyte, Inc.
MXCT
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Category
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -4.50 | 22.02% |
| 2025 | -3.69 | -65.26% |
| 2024 | -10.62 | -16.99% |
| 2023 | -12.80 | -45.67% |
| 2022 | -23.56 | -51.32% |
| 2021 | -48.39 | -51.58% |
| 2020 | -99.94 | 34.41% |
| 2019 | -74.35 | -24.21% |
| 2018 | -98.10 | 17.65% |
| 2017 | -83.39 | -51.04% |
| 2016 | -170.31 | -66.69% |
| 2015 | -511.24 | 4,691.02% |
| 2014 | -10.67 | -98.62% |
| 2013 | -771.24 | 107.51% |
| 2012 | -371.65 | 0.00% |
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| -8.15 | 80.92% |
US
|
|
| 34.39 | -863.87% |
US
|
|
| -31.59 | 601.70% |
US
|
|
| -25.99 | 477.13% |
AU
|
|
| 25.67 | -670.15% |
BE
|
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.
Questions about MaxCyte, Inc.'s P/E ratio
What is MaxCyte, Inc.'s P/E ratio?
MaxCyte, Inc.'s P/E ratio is -4.50, as of Nov 2026.
What was MaxCyte, Inc.'s P/E ratio in 2025?
In 2025, MaxCyte, Inc.'s P/E ratio was -3.69, compared with -10.62 in 2024.
How has MaxCyte, Inc.'s P/E ratio changed since 2020?
From 2020 to 2025, MaxCyte, Inc.'s P/E ratio was highest in 2025 (-3.69) and lowest in 2020 (-99.94).
How does MaxCyte, Inc.'s P/E ratio compare with similar companies?
MaxCyte, Inc.'s P/E ratio (-4.50) is higher than that of 3 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 34.39.